Company facts
- Founded
- 2024
- Headquarters
- Switzerland
About
More than 50% of patients with cancer do not respond to the drug given to them. We developed a personalized, ex-vivo, single-cell method that can test 120+ drugs in parallel on a patient's live cancer and healthy cells. The test can identify which drugs and combinations are most effective for this patient, helping onco…